Interius Biotherapeutics reports preclinical data on in vivo CAR vector for B-cell malignancies
June 21, 2023
Interius Biotherapeutics Inc. has reported preclinical data demonstrating the potential of its lead program to generate biologically active chimeric antigen receptor (CAR) cells directly in vivo for the treatment of B-cell malignancies.